Literature DB >> 11294897

Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, Stat activation, and phosphatidylinositol 3-kinase activation.

K C Hart1, S C Robertson, D J Donoghue.   

Abstract

Fibroblast growth factor receptor 3 (FGFR3) mutations are frequently involved in human developmental disorders and cancer. Activation of FGFR3, through mutation or ligand stimulation, results in autophosphorylation of multiple tyrosine residues within the intracellular domain. To assess the importance of the six conserved tyrosine residues within the intracellular domain of FGFR3 for signaling, derivatives were constructed containing an N-terminal myristylation signal for plasma membrane localization and a point mutation (K650E) that confers constitutive kinase activation. A derivative containing all conserved tyrosine residues stimulates cellular transformation and activation of several FGFR3 signaling pathways. Substitution of all nonactivation loop tyrosine residues with phenylalanine rendered this FGFR3 construct inactive, despite the presence of the activating K650E mutation. Addition of a single tyrosine residue, Y724, restored its ability to stimulate cellular transformation, phosphatidylinositol 3-kinase activation, and phosphorylation of Shp2, MAPK, Stat1, and Stat3. These results demonstrate a critical role for Y724 in the activation of multiple signaling pathways by constitutively activated mutants of FGFR3.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11294897      PMCID: PMC32277          DOI: 10.1091/mbc.12.4.931

Source DB:  PubMed          Journal:  Mol Biol Cell        ISSN: 1059-1524            Impact factor:   4.138


  53 in total

Review 1.  Apoptosis and cancer drug targeting.

Authors:  W R Sellers; D E Fisher
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

Review 2.  Phosphatidylinositol-3 kinase dependent pathways: the role in control of cell growth, survival, and malignant transformation.

Authors:  M A Krasilnikov
Journal:  Biochemistry (Mosc)       Date:  2000-01       Impact factor: 2.487

Review 3.  Fibroblast growth factor receptors: lessons from the genes.

Authors:  D Burke; D Wilkes; T L Blundell; S Malcolm
Journal:  Trends Biochem Sci       Date:  1998-02       Impact factor: 13.807

4.  Activation of H-ras61L-specific signaling pathways does not require posttranslational processing of H-ras.

Authors:  K C Hart; S C Robertson; D J Donoghue
Journal:  Exp Cell Res       Date:  2000-05-25       Impact factor: 3.905

5.  High-efficiency transformation of mammalian cells by plasmid DNA.

Authors:  C Chen; H Okayama
Journal:  Mol Cell Biol       Date:  1987-08       Impact factor: 4.272

6.  Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4.

Authors:  K C Hart; S C Robertson; M Y Kanemitsu; A N Meyer; J A Tynan; D J Donoghue
Journal:  Oncogene       Date:  2000-07-06       Impact factor: 9.867

7.  A tyrosine-phosphorylated carboxy-terminal peptide of the fibroblast growth factor receptor (Flg) is a binding site for the SH2 domain of phospholipase C-gamma 1.

Authors:  M Mohammadi; A M Honegger; D Rotin; R Fischer; F Bellot; W Li; C A Dionne; M Jaye; M Rubinstein; J Schlessinger
Journal:  Mol Cell Biol       Date:  1991-10       Impact factor: 4.272

8.  GTPase-activating protein and phosphatidylinositol 3-kinase bind to distinct regions of the platelet-derived growth factor receptor beta subunit.

Authors:  A Kazlauskas; A Kashishian; J A Cooper; M Valius
Journal:  Mol Cell Biol       Date:  1992-06       Impact factor: 4.272

9.  Distinct phosphotyrosines on a growth factor receptor bind to specific molecules that mediate different signaling pathways.

Authors:  W J Fantl; J A Escobedo; G A Martin; C W Turck; M del Rosario; F McCormick; L T Williams
Journal:  Cell       Date:  1992-05-01       Impact factor: 41.582

10.  Phosphorylation sites in the PDGF receptor with different specificities for binding GAP and PI3 kinase in vivo.

Authors:  A Kashishian; A Kazlauskas; J A Cooper
Journal:  EMBO J       Date:  1992-04       Impact factor: 11.598

View more
  42 in total

Review 1.  Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias.

Authors:  Silvie Foldynova-Trantirkova; William R Wilcox; Pavel Krejci
Journal:  Hum Mutat       Date:  2011-11-16       Impact factor: 4.878

2.  MUC1 oncoprotein functions in activation of fibroblast growth factor receptor signaling.

Authors:  Jian Ren; Deepak Raina; Wen Chen; Guilan Li; Lei Huang; Donald Kufe
Journal:  Mol Cancer Res       Date:  2006-11       Impact factor: 5.852

3.  FGFR4 and its novel splice form in myogenic cells: Interplay of glycosylation and tyrosine phosphorylation.

Authors:  Boguslaw A Kwiatkowski; Irina Kirillova; Robert E Richard; David Israeli; Zipora Yablonka-Reuveni
Journal:  J Cell Physiol       Date:  2008-06       Impact factor: 6.384

Review 4.  FGFR3-related dwarfism and cell signaling.

Authors:  Daisuke Harada; Yoshitaka Yamanaka; Koso Ueda; Hiroyuki Tanaka; Yoshiki Seino
Journal:  J Bone Miner Metab       Date:  2008-12-09       Impact factor: 2.626

5.  Nordihydroguaiaretic acid inhibits an activated fibroblast growth factor receptor 3 mutant and blocks downstream signaling in multiple myeloma cells.

Authors:  April N Meyer; Christopher W McAndrew; Daniel J Donoghue
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

6.  Functional characteristics of mesenchymal stem cells derived from the adipose tissue of a patient with achondroplasia.

Authors:  Jeong-Ran Park; Hanbyeol Lee; Chung-Hyo Kim; Seok-Ho Hong; Kwon-Soo Ha; Se-Ran Yang
Journal:  In Vitro Cell Dev Biol Anim       Date:  2016-04-08       Impact factor: 2.416

7.  Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition.

Authors:  Jonathan R St-Germain; Paul Taylor; Jiefei Tong; Lily L Jin; Ana Nikolic; Ian I Stewart; Robert M Ewing; Moyez Dharsee; Zhihua Li; Suzanne Trudel; Michael F Moran
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-09       Impact factor: 11.205

8.  FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.

Authors:  Lucie C Kompier; Irene Lurkin; Madelon N M van der Aa; Bas W G van Rhijn; Theo H van der Kwast; Ellen C Zwarthoff
Journal:  PLoS One       Date:  2010-11-03       Impact factor: 3.240

9.  A novel interaction between fibroblast growth factor receptor 3 and the p85 subunit of phosphoinositide 3-kinase: activation-dependent regulation of ERK by p85 in multiple myeloma cells.

Authors:  Lisa Salazar; Tamara Kashiwada; Pavel Krejci; Paul Muchowski; Daniel Donoghue; William R Wilcox; Leslie Michels Thompson
Journal:  Hum Mol Genet       Date:  2009-03-13       Impact factor: 6.150

10.  Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner.

Authors:  E di Martino; C G L'Hôte; W Kennedy; D C Tomlinson; M A Knowles
Journal:  Oncogene       Date:  2009-09-14       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.